Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT00829166
What this trial is testing

Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 991
Testing effectiveness (Phase 2)Ended earlyNCT02990845
What this trial is testing

Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Premenopausal Breast Cancer
National Taiwan University Hospital 16
Testing effectiveness (Phase 2)Looking for participantsNCT04965766
What this trial is testing

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerAdvanced Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris 139
Testing effectiveness (Phase 2)Looking for participantsNCT06224673
What this trial is testing

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Who this might be right for
HER2 Low Breast CarcinomaTriple Negative Breast CancerHormone-receptor-positive Breast Cancer+1 more
Laura Huppert, MD, BA 36
Testing effectiveness (Phase 2)WithdrawnNCT01361945
What this trial is testing

AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerHER-2 Positive Breast Cancer+1 more
Texas Tech University Health Sciences Center, El Paso
Testing effectiveness (Phase 2)Looking for participantsNCT07002177
What this trial is testing

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Who this might be right for
Metastatic Breast CancerBreast Cancer Stage IBreast Cancer Stage II+2 more
Forward Pharmaceuticals Co., Ltd. 196
Large-scale testing (Phase 3)Looking for participantsNCT05646862
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 420
Testing effectiveness (Phase 2)Ended earlyNCT00657137
What this trial is testing

APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)

Who this might be right for
Breast Cancer
Tragara Pharmaceuticals, Inc. 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT04550494
What this trial is testing

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Castration-Resistant Prostate Carcinoma+28 more
National Cancer Institute (NCI) 29
Testing effectiveness (Phase 2)Looking for participantsNCT07486089
What this trial is testing

Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)

Who this might be right for
Breast Cancer (Locally Advanced or Metastatic)HER2-positive Breast CancerTriple-Negative Breast Cancer (TNBC)
Beijing Biotech 60
Testing effectiveness (Phase 2)Ended earlyNCT05091528
What this trial is testing

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Colorectal Cancer+1 more
Silverback Therapeutics 2
Early research (Phase 1)Study completedNCT02058381
What this trial is testing

A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Pre-menopausal Breast CancerPI3K Pathway Inhibition
Novartis Pharmaceuticals 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07336771
What this trial is testing

JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast Cancer (LABC)
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 60
Large-scale testing (Phase 3)Looking for participantsNCT05894239
What this trial is testing

Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Hoffmann-La Roche 230
Testing effectiveness (Phase 2)Active Not RecruitingNCT02311933
What this trial is testing

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Who this might be right for
Recurrent Breast CarcinomaStage III Breast Cancer AJCC v7Stage IIIA Breast Cancer AJCC v7+3 more
National Cancer Institute (NCI) 81
Not applicableEnded earlyNCT04778982
What this trial is testing

Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer

Who this might be right for
HER2-positive Metastatic Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 4
Testing effectiveness (Phase 2)Study completedNCT02028364
What this trial is testing

Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women

Who this might be right for
Breast Cancer
Jules Bordet Institute 55
Post-approval studies (Phase 4)Ended earlyNCT03220178
What this trial is testing

Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy

Who this might be right for
Breast Neoplasm
Palleos Healthcare GmbH 532
Large-scale testing (Phase 3)Looking for participantsNCT07377643
What this trial is testing

IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. 540
Not applicableApproved For MarketingNCT04220203
What this trial is testing

Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer
Next Page